{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T21:30:37Z","timestamp":1792963837405,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmoop.2025.105301","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T17:10:10Z","timestamp":1748797810000},"page":"105301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings"],"prefix":"10.1016","volume":"10","author":[{"given":"K.","family":"Takagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-4692","authenticated-orcid":false,"given":"T.","family":"Shukuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tsugitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-8786","authenticated-orcid":false,"given":"T.","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mamesaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-5090","authenticated-orcid":false,"given":"T.","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-220X","authenticated-orcid":false,"given":"M.","family":"Tachihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5026-8078","authenticated-orcid":false,"given":"H.","family":"Gyotoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3774-8915","authenticated-orcid":false,"given":"T.","family":"Tozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-3988","authenticated-orcid":false,"given":"M.","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-8151","authenticated-orcid":false,"given":"A.","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1673-2260","authenticated-orcid":false,"given":"H.","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-8789","authenticated-orcid":false,"given":"H.","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5461-9894","authenticated-orcid":false,"given":"K.","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0513-2860","authenticated-orcid":false,"given":"Y.","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Tokito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-5233","authenticated-orcid":false,"given":"H.","family":"Ashinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-8641","authenticated-orcid":false,"given":"Y.","family":"Tsukita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-7202","authenticated-orcid":false,"given":"Y.","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2025.105301_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jjco\/hyz203","article-title":"National incidence and initial therapy for thymic carcinoma in Japan: based on analysis of hospital-based cancer registry data, 2009-2015","volume":"50","author":"Koizumi","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105301_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102645","article-title":"The contribution of rural\/urban residence to incidence and survival in thymoma and thymic carcinoma, a retrospective cohort study of the SEER 2000-2020 database","volume":"92","author":"Cascone","year":"2024","journal-title":"Cancer Epidemiol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105301_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227197","article-title":"Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States","volume":"14","author":"Hsu","year":"2019","journal-title":"PLoS One"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2025.105301_bib4","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"ESMO Guidelines Committee. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105301_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2019.10.016","article-title":"Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203","volume":"139","author":"Tsukita","year":"2020","journal-title":"Lung Cancer"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105301_bib6","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1002\/cam4.3385","article-title":"Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma","volume":"9","author":"Okuma","year":"2020","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105301_bib7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","article-title":"A Phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma","volume":"13","author":"Gbolahan","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.105301_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2019.09.015","article-title":"Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies","volume":"137","author":"Hellyer","year":"2019","journal-title":"Lung Cancer"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105301_bib9","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105301_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105301_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105301_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105301_bib13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jtho.2023.04.009","article-title":"STYLE (NCT03449173): a phase 2 trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines","volume":"18","author":"Proto","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105301_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105301_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"10126","key":"10.1016\/j.esmoop.2025.105301_bib16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105301_bib17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105301_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107557","article-title":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: results from the multicenter, phase 2 REMORA trial","volume":"191","author":"Niho","year":"2024","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105301_bib20","doi-asserted-by":"crossref","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105301_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.105301_bib22","series-title":"Guidelines for Diagnosis and Treatment of Lung Cancer\/Malignant Pleural Mesothelioma\/Thymic Tumor 2024","year":"2024"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105301_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2007.13.1144","article-title":"Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599","volume":"26","author":"Ramalingam","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105301_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/JTO.0b013e3182370e02","article-title":"Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390)","volume":"7","author":"Laskin","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105301_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clon.2014.12.002","article-title":"Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study","volume":"27","author":"Wozniak","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105301_bib26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11523-024-01067-8","article-title":"Anti-angiogenic tyrosine kinase inhibitor-related toxicities among cancer patients: a systematic review and meta-analysis","volume":"19","author":"Van Nguyen","year":"2024","journal-title":"Target Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105301_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105301_bib28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105301_bib29","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105301_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2326","article-title":"LBA83 PECATI: a phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma","volume":"35","author":"Remon Masip","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105301_bib31","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1007\/s12325-020-01433-8","article-title":"Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan","volume":"37","author":"Takahashi","year":"2020","journal-title":"Adv Ther"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105301_bib32","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial","volume":"35","author":"Brose","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105301_bib33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1507\/endocrj.EJ20-0754","article-title":"Prognostic significance of 8 weeks\u2019 relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients","volume":"68","author":"Fukuda","year":"2021","journal-title":"Endocr J"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105301_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231828","article-title":"Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma","volume":"15","author":"Kirino","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105301_bib35","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.21873\/anticanres.13710","article-title":"Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma","volume":"39","author":"Takahashi","year":"2019","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105301_bib36","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers11111769","article-title":"Response to lenvatinib is associated with optimal relative dose intensity in hepatocellular carcinoma: experience in clinical settings","volume":"11","author":"Sasaki","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105301_bib37","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1210\/clinem\/dgab731","article-title":"A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer","volume":"107","author":"Brose","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105301_bib38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105301_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","article-title":"Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Shukuya","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105301_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000350","article-title":"Propensity score\u2013weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non\u2013small cell lung cancer (WJOG10217L)","volume":"8","author":"Kato","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.105301_bib41","article-title":"Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer","volume":"4","author":"Sasaki","year":"2020","journal-title":"ESMO Open"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:13:09Z","timestamp":1751886789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925011706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2059702925011706"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105301","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105301"}}